Detalhe da pesquisa
1.
Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.
BMC Med
; 18(1): 298, 2020 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33143745
2.
Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases.
J Neuroinflammation
; 16(1): 219, 2019 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727097
3.
Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients.
J Autoimmun
; 88: 83-90, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29066027
4.
Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis.
Ann Neurol
; 73(1): 86-94, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23225573
5.
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Mult Scler
; 19(11): 1454-61, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23439578
6.
Regulation of the programmed cell death protein 1/programmed cell death ligand 1 axis in relapsing-remitting multiple sclerosis.
Brain Commun
; 5(4): fcad206, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37564830
7.
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation.
J Neuroinflammation
; 9: 93, 2012 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-22591862
8.
HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.
Am J Hum Genet
; 83(2): 219-27, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18656179
9.
The Aryl Hydrocarbon Receptor-Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
; 8(5)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34301821
10.
Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS.
Neurol Neuroimmunol Neuroinflamm
; 8(2)2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33361385
11.
Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease.
Ann Neurol
; 66(6): 833-42, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20033986
12.
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
J Neuroimmunol
; 326: 19-27, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30447419
13.
Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection.
Ann Neurol
; 62(5): 458-67, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17703460
14.
CD8 T-cell subsets and viral load in the cerebrospinal fluid of therapy-naive HIV-infected individuals.
AIDS
; 21(2): 250-3, 2007 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-17197822
15.
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
PLoS One
; 12(2): e0170395, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28170401
16.
Accumulation of class switched IgD-IgM- memory B cells in the cerebrospinal fluid during neuroinflammation.
J Neuroimmunol
; 180(1-2): 33-9, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16952404
17.
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.
Brain
; 128(Pt 7): 1667-76, 2005 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15800022
18.
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.
PLoS One
; 11(11): e0162752, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27806057
19.
The immune response at onset and during recovery from Borrelia burgdorferi meningoradiculitis.
Arch Neurol
; 60(6): 849-55, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12810490
20.
The role of the polio virus receptor and the herpesvirus entry mediator B genes for the development of MS.
J Neuroimmunol
; 156(1-2): 171-7, 2004 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-15465608